425: Pieris Pharmaceuticals to Merge with Palvella Therapeutics, Creating Rare Disease Focused Company

Pieris Pharmaceuticals and Palvella Therapeutics have announced a definitive merger agreement to form a clinical-stage biopharmaceutical company focused on rare genetic skin diseases.

Summary

• Pieris Pharmaceuticals and Palvella Therapeutics have entered into a definitive merger agreement to create a company focused on developing treatments for rare genetic skin diseases.
• The combined company will focus on Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
• Pre-merger Pieris stockholders are expected to own approximately 18% of the combined company, while pre-merger Palvella stockholders are expected to own approximately 82%, prior to the issuance of shares under a concurrent private financing.
• Palvella has secured commitments for a $78.9 million concurrent private financing co-led by BVF Partners, L.P., and Frazier Life Sciences.
• The combined company is expected to have approximately $80.5 million in cash and cash equivalents at closing, providing a cash runway into the second half of 2027.
• Pieris pre-merger stockholders will receive a contingent value right (CVR) for potential payments from existing partnership agreements.
• The merger is expected to close in the fourth quarter of 2024, pending stockholder approval and regulatory requirements.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the potential benefits for both companies and their stockholders. The secured financing and expected cash runway contribute to a favorable sentiment.

Positives

• The merger creates a focused entity with a late-stage clinical program.
• QTORIN rapamycin has received FDA Breakthrough Therapy Designation and Fast Track Designation for microcystic LMs.
• The concurrent private financing provides substantial funding to advance clinical trials.
• The CVR offers Pieris stockholders potential upside from existing partnership agreements.
• QTORIN rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations, if approved.

Risks

• The merger is subject to stockholder approval and regulatory requirements.
• Clinical trial outcomes are uncertain.
• The CVR may not result in any payments to Pieris stockholders.
• The combined company will be reliant on the success of QTORIN rapamycin.
• The company may face challenges in obtaining regulatory approval and commercializing QTORIN rapamycin.

Future Outlook

The combined company will focus on developing and commercializing QTORIN rapamycin and advancing it through clinical trials, with the goal of obtaining regulatory approval and commercializing the product for rare genetic skin diseases.

Management Comments

• Wes Kaupinen, Founder and CEO of Palvella, stated the merger will allow Palvella to become a publicly traded company and pursue its vision of becoming the leading rare disease company.
• Stephen S. Yoder, President and CEO of Pieris, stated the transaction represents Pieris deep commitment to delivering value to its stockholders and provides the opportunity for upside in an attractive, late-stage, rare disease company.

Industry Context

The merger reflects a trend in the biopharmaceutical industry of companies combining to leverage resources and expertise, particularly in the rare disease space. This allows for greater focus and efficiency in developing and commercializing specialized therapies.

Comparison to Industry Standards

• The $78.9 million concurrent private financing is a significant amount for a company in the rare disease space, indicating strong investor confidence.
• The cash runway into the second half of 2027 provides financial stability for the combined company to achieve key clinical milestones.
• The CVR structure is a common mechanism used in mergers to provide existing stockholders with potential upside from legacy assets.

Stakeholder Impact

• Pieris stockholders will receive CVRs, providing potential upside from legacy assets.
• Palvella stockholders will gain access to public markets and additional funding.
• Patients with rare genetic skin diseases may benefit from the development of new therapies.

Next Steps

• Obtain stockholder approval from both Pieris and Palvella.
• File a registration statement with the SEC.
• Close the concurrent private financing.
• Complete the merger in the fourth quarter of 2024.
• Advance QTORIN rapamycin through clinical trials.

Key Dates